EGCG (Epigallocatechin Gallate).

Caffeine raises circulating catecholamines by blocking adenosine receptors, while EGCG slows catecholamine breakdown through catechol-O-methyltransferase. The two therefore act on the same pathway from opposite ends, which is why they occur together in the leaf and in most thermogenic formulas. Isolated EGCG carries no caffeine of its own, so any stimulant load in a product comes from what was added.

Theanine and EGCG both come from the same leaf but do entirely different work: theanine is a glutamine analogue that crosses into the brain, EGCG is a gallated polyphenol that mostly does not. Purified EGCG carries no theanine, so recreating the leaf's balance means adding it back. The pairing is compositional logic rather than a tested combination.

EGCG binds non-heme iron in the gut lumen and forms a complex the intestinal transporter cannot take up, which is the same reason tea with a meal lowers iron absorption. The effect is largest when both are in the stomach together. Separating an EGCG dose from an iron dose by a couple of hours is standard practice.

Ferrous sulfate delivers a large bolus of free non-heme iron, which is exactly the species EGCG chelates most readily. Taken together, less of the iron dose is available for uptake. Vitamin C in the same dose partly counteracts the binding by holding iron in its reduced form.

Ascorbate reduces the phenoxyl radical formed after EGCG donates an electron, returning it to its reduced form, and it also keeps iron in the ferrous state where polyphenol binding is weaker. So the pairing does two separate things at once. Both are solution chemistry, not clinical outcomes.

Zinc is a divalent cation and EGCG's catechol and galloyl groups bind it in the gut lumen. Co-dosing reduces the free zinc fraction available for uptake at that moment. Spacing the doses resolves it.

Calcium forms poorly soluble complexes with galloylated catechins, lowering the free fraction of both. This matters most when a mineral supplement and a concentrated polyphenol dose are swallowed together. It is a timing question, not a reason to drop either.

EGCG chelates copper, and copper-catechin complexes are also the setting in which high catechin concentrations can behave as pro-oxidants rather than antioxidants. Co-dosing lowers free copper for uptake. Read this as chemistry rather than a demonstrated status effect.

EGCG inhibits dihydrofolate reductase in laboratory systems, the enzyme that converts folic acid into its usable reduced form. That gives a mechanistic reason to space a concentrated EGCG dose from a folic acid dose, especially where folate intake is already marginal. This is enzymology and a status-marker concern, not a demonstrated deficiency outcome.

Methylfolate enters the folate cycle downstream of dihydrofolate reductase, the step EGCG inhibits in laboratory systems, so it bypasses the point of interference. That makes the interaction a reason to choose where in the cycle folate is supplied rather than a reason to avoid the pairing. The reasoning is mechanistic and has not been measured as a pair.

EGCG is heavily glucuronidated during first pass, and piperine inhibits UDP-glucuronosyltransferase and intestinal efflux. Animal pharmacokinetic work reports higher EGCG exposure when the two are given together. Higher exposure of a metabolite-limited molecule is a pharmacokinetic result, not an outcome.

Curcumin and EGCG have been supplemented together in a randomised design rather than each on its own. Both are poorly absorbed polyphenols that compete for the same glucuronidation and sulfation enzymes, which cuts in two directions: shared signalling targets on one hand, metabolic competition on the other. One trial of the pair is a starting point.

EGCG and ellagic acid have been studied together as a combination alongside ketone bodies, examining cellular energy handling. Both are polyphenols reworked extensively by gut bacteria before they reach the circulation. Regard the pairing as exploratory.

Most EGCG never crosses the gut wall intact; colonic bacteria ring-open it into valerolactones and phenolic acids that then enter the circulation. A twelve-week combined polyphenol supplementation study looked at exactly this interaction between the microbiota and host metabolism, and reported sex-specific patterns. Which metabolites a person makes depends on the bacteria they carry.

A fermentable fibre changes the colonic population that converts EGCG into its absorbable metabolites. That is a plausible route by which a prebiotic changes what a person actually absorbs from a polyphenol dose. The link is mechanistic and unmeasured as a pair.

Milk proteins bind EGCG through hydrogen bonding and hydrophobic contact, which is the reason milk lowers free catechin in brewed tea. Adding purified EGCG to a casein shake reduces the unbound fraction available for absorption. The complex is inert; it changes what is free, nothing more.

Whey binds polyphenols in the same manner as casein, generally more weakly and more sensitive to pH. Mixing EGCG into a protein shake lowers free catechin at that dose. Separating them in time is the usual answer.

Both are polyphenols cleared largely by glucuronidation and sulfation and both are studied for their influence on metabolic signalling. Stacked, they act on overlapping targets while competing for the same conjugation capacity. Say both halves of that rather than only the flattering one.

Quercetin occupies the same sulfotransferase and UDP-glucuronosyltransferase capacity that clears EGCG, and laboratory work reports higher EGCG concentrations when quercetin is present. Less conjugation means more parent molecule surviving first pass. That is a pharmacokinetic effect and does not by itself say anything about an outcome.

A lipid load changes how a poorly soluble polyphenol partitions during digestion, and long-chain omega-3 fatty acids influence lipid handling by their own route. The two touch the same broad process from unrelated directions. Read the pairing as mechanistic.

Alpha-tocopherol works inside the lipid membrane while EGCG works mainly in the aqueous phase, and phenolic antioxidants can regenerate the tocopheroxyl radical after it has quenched a lipid radical. The two therefore cover different compartments of the same defence. This is solution chemistry, not a clinical claim.

At high concentration and with transition metals present, EGCG can act as a pro-oxidant rather than an antioxidant, and a thiol donor shifts that local balance. The chemistry is concentration dependent and well described in vitro. It has not been quantified as a supplement pairing in people.

Tyrosine is the precursor for dopamine and noradrenaline, while EGCG slows their inactivation through catechol-O-methyltransferase. Supplying more precursor while slowing clearance acts on the same pool from both ends. The direction follows from the biochemistry; the size in people does not.

Both influence blood glucose after a meal, by unrelated routes. Combined, two influences act on the same normal process, which matters most for anyone tracking glucose closely. State the overlap without assuming it multiplies.

Chromium is studied in the context of normal insulin signalling and EGCG in the context of post-meal glucose. Metabolic formulas pair them for that reason. The combination is formulation convention rather than a measured result.

Carnitine moves long-chain fatty acids into the mitochondrion while EGCG is studied for its influence on substrate selection. Both touch the same fuel-choice step from different positions. The pairing is mechanistic and untested.